http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2007507534-A

Outgoing Links

Predicate Object
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-567
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-34
classificationIPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J1-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-567
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-565
filingDate 2004-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 2007-03-29-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber JP-2007507534-A
titleOfInvention Sustained three-phase contraception
abstract A continuous three-phase oral contraceptive method is disclosed. According to the disclosed method, a combination of estrogen and progestin is administered over at least 42 consecutive days, followed by a 4-8 day hormone free period. Estrogens and progestins are administered at a contraceptive effective daily dosage for at least two consecutive cycles of at least 21 days, where the estrogen dosage remains constant for each cycle and the progestin dosage is three-phase for each daily cycle Increase with.
priorityDate 2003-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-H1129481-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2003048836-A
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5463980
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6540478
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396137
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5994
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID449247578
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419554137
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID433323226
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419503777
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID134688829
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5360970
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399016
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226423899
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226423900
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5991

Total number of triples: 45.